Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

NCT01799941 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

Pseudobulbar Affect (PBA)
Stroke
Dementia
Traumatic Brain Injury (TBI)

Interventions

DRUG: Nuedexta (DM 20 mg/Q 10 mg)

Sponsor

Avanir Pharmaceuticals